Clinical trial
A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of BG2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women.
NCT05620355 is registered in ClinicalTrials.gov with Bio Genuine (Shanghai) Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of BG2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women.
- Lead sponsor
- Bio Genuine (Shanghai) Biotech Co., Ltd.
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- December 16, 2022
- Completion date
- March 31, 2025
- Enrollment
- 312 (estimated)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.
heavy menstrual bleeding, uterine fibroids